Abiopharma

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: DISCLOSURE OF CHANGES IN INTEREST OF DIRECTOR - DR NG CHIN SIAU

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Mandatory Cash Dividend/ Distribution:

FDA approve ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

FDA approve TRAZODONE HYDROCHLORIDE

FDA approve FINASTERIDE

FDA approve ITRACONAZOLE

FDA approve PLERIXAFOR

FDA approve NEFAZODONE HYDROCHLORIDE

FDA approve MONTELUKAST SODIUM

FDA approve MONTELUKAST SODIUM

FDA approve THEOPHYLLINE

FDA approve AMITRIPTYLINE HYDROCHLORIDE

FDA approve THEOPHYLLINE

FDA approve DOLUTEGRAVIR AND LAMIVUDINE